TSHA Hedge Fund Ownership (Q2 2026)

Taysha Gene Therapies Inc (TSHA)

204 + Investors. Track Smart Money conviction in TSHA. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — TSHA

Based on 204 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds added TSHA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

204 hedge funds hold TSHA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +40% more funds vs a year ago

fund count last 6Q

+58 new funds entered over the past year (+40% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 66% buying

138 buying72 selling

Last quarter: 138 funds were net buyers (42 opened a brand new position + 96 added to an existing one). Only 72 were sellers (44 trimmed + 28 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+7 vs last Q)

new funds entering per quarter

Funds opening a new TSHA position: 29 → 67 → 35 → 42. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

📌

Mixed — 36% long-term, 34% new

■ 36% conviction (2yr+) ■ 29% medium ■ 34% new

Of the 204 current holders: 74 (36%) held >2 years, 60 held 1–2 years, and 70 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💰

Value +69% but shares only +12% — price-driven

Value

+68%

+12%

Last quarter: the total dollar value of institutional holdings rose +69%, but actual share count only changed +12%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

📊

Peak discovery — momentum slowing

44 → 29 → 67 → 35 → 42 new funds/Q

New funds entering each quarter: 29 → 67 → 35 → 42. TSHA is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.

🏛️

Veteran-anchored — 44% veterans vs 39% newcomers

■ 44% veterans ■ 17% 1-2yr ■ 39% new

Entry-cohort mix of 209 holders: 92 (44%) are 2+ year veterans, 36 entered 1–2 years ago, and 81 (39%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 40% AUM from top-100 funds

40% from top-100 AUM funds

48 of 204 holders are among the 100 largest funds by AUM, controlling 40% of total institutional value in TSHA. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

4.3

out of 10

Moderate Exit Risk

Exit risk score 4.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	204	190	7.37%
13F Shares	298M	265M	12.23%
Total Value	$2.04B	$1.21B	68.52%
New Positions	42	35	+7
Increased Positions	96	68	+28
Closed Positions	28	39	-11
Reduced Positions	41	49	-8
Total Calls	3	4	-25.0%
Total Puts	2	3	-33.33%
PUT/CALL Ratio	0.67	0.75	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

204

190

7.37%

13F Shares

298M

265M

12.23%

Total Value

$2.04B

$1.21B

68.52%

New Positions

Increased Positions

+28

Closed Positions

-11

Reduced Positions

-8

Total Calls

-25.0%

Total Puts

-33.33%

PUT/CALL Ratio

0.67

0.75

Bullish

Institutional Holders (2026 Q2)

204 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in TSHA. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 TSHA holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Octagon Capital Advisors LP	5.93%	9,693,244	$66.0M
2	B Group, Inc.	5.76%	1,800,556	$12.3M
3	Vestal Point Capital, LP	3.09%	19,415,000	$132.2M
4	Acuta Capital Partners, LLC	2.67%	561,808	$3.8M
5	Heights Capital Management, Inc	2.36%	1,500,000	$10.2M
6	Monashee Investment Management LLC	2.29%	200,000	$1.4M
7	MPM BioImpact LLC	1.87%	4,500,000	$30.6M
8	Seven Fleet Capital Management LP	1.64%	1,504,400	$9.9M
9	Avoro Capital Advisors LLC	1.46%	23,888,888	$162.7M
10	Quantum Private Wealth, LLC	1.42%	812,027	$5.5M
11	Ra Capital Management, L.P.	1.39%	23,555,648	$160.4M
12	Siren, L.L.C.	1.36%	9,846,579	$67.1M
13	Palo Alto Investors LP	1.31%	1,391,382	$9.5M
14	Casdin Capital, LLC	1.11%	3,250,000	$22.1M
15	ADAR1 Capital Management, LLC	0.95%	3,040,466	$20.7M
16	Sands Capital Alternatives, LLC	0.80%	724,873	$4.9M
17	Rtw Investments, LP	0.79%	13,560,258	$92.3M
18	Rice Hall James & Associates, LLC	0.66%	1,992,229	$13.6M
19	Affinity Asset Advisors, LLC	0.54%	1,750,000	$11.9M
20	Affinity Wealth Management LLC	0.51%	576,808	$3.9M
21	Diadema Partners LP	0.45%	522,619	$3.6M
22	Red Reef Advisors LLC	0.41%	65,950	$449K
23	Granahan Investment Management, LLC	0.32%	1,305,177	$8.9M
24	Persistent Asset Partners Ltd	0.27%	133,411	$909K
25	nVerses Capital, LLC	0.26%	25,152	$171K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Taysha Gene Therapies Inc (TSHA)

What does the Smart Money Trend signal show for TSHA?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added TSHA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for TSHA?

More buyers than sellers — 66% buying: Last quarter: 138 funds were net buyers (42 opened a brand new position + 96 added to an existing one). Only 72 were sellers (44 trimmed + 28 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for TSHA holders?

Elite ownership — 40% AUM from top-100 funds: 48 of 204 holders are among the 100 largest funds by AUM, controlling 40% of total institutional value in TSHA. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held TSHA?

Mixed — 36% long-term, 34% new: Of the 204 current holders: 74 (36%) held >2 years, 60 held 1–2 years, and 70 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Taysha Gene Therapies Inc (TSHA)

Smart Money Signals — TSHA

Buying streak — 1 quarter in a row

At the ownership peak (100% of max)

Fast accumulation — +40% more funds vs a year ago

More buyers than sellers — 66% buying

More new buyers each quarter (+7 vs last Q)

Mixed — 36% long-term, 34% new

Value +69% but shares only +12% — price-driven

Peak discovery — momentum slowing

Veteran-anchored — 44% veterans vs 39% newcomers

Elite ownership — 40% AUM from top-100 funds

Institutional Sentiment Summary — TSHA

Hedge Fund Ownership: TSHA

Market Analysis: TSHA

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: TSHA

Hedge Fund Positioning: TSHA

Statistics: TSHA

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Taysha Gene Therapies Inc (TSHA)

Welcome to 13Foresight!